常用治疗阿尔茨海默病的药物对血管性痴呆的疗效观察

目的：观察吡拉西坦、双氢麦角碱、多奈哌齐、卡巴拉汀、美金刚等常用治疗阿尔茨海默病（AD）的药物对血管性痴呆的疗效。方法：将2010年8月—2012年8月收治的200例血管性痴呆患者以随机抽样法分为5组,每组40例,分别应用吡拉西坦、双氢麦角碱、多奈哌齐、卡巴拉汀、美金刚治疗;于治疗前、治疗3个月后对5组患者进行简易智能精神状态量表（MMSE）及日常生活能力量表（ADL）评分,比较5组的差异,随时记录药品不良反应。结果：吡拉西坦组治疗前后MMSE及ADL评分比较,差异无统计学意义（P〉0.05）。其余4组各组内治疗前后MMSE及ADL评分比较,差异均有统计学意义（P〈0.05）;这4组间治疗后MMSE及ADL评分比较,差异无统计学意义（P〉0.05）。结论：双氢麦角碱、多奈哌齐、卡巴拉汀、美金刚等常用治疗AD的药物可用于治疗血管性痴呆。

Curative Effects of Common Anti-Alzheimer Disease Drugs on Vascular Dementia

OBJECTIVE ：ABSTRCT To evaluate the curative effects of some common anti-AD （Mzheimer Disease） drugs including piracetam, dihydroergotoxine, donepezil, rivastigmine and memantine on vascular dementia. METHODS： 200 patients with vascular dementia treated in our hospital from Aug. 2010 to Aug. 2012 were assigned to 5 groups of 40 each to be treated with one of the following 5 drugs： piracetam, dihydroergotoxine, donepezil, rivastigmine or memantine. Mini- mental state examination （MMSE） and activity of daily living scale （ADL） were employed for evaluation and comparison of the 5 groups before the treatment and after three months of treatment, with adverse drug reactions recorded timely. RESULTS： With regard to MMSE and ADL before and after treatment, piracetam-treated group showed no significant differences after treatment （P 〉0. 05）, yet the other four groups showed significant differences after treatment as compared with before treatment （P 〈 0. 05）. After treatment, there were no significant differences across these 4 groups with regard toMMSE and ADL （P 〉 0. 05）. CONCLUSION ： The common anti-AD drugs like dihydroergotoxine, donepezil, rivastigmine and memantine can be used to treat the patients with vascular dementia.